Competitive Landscape GLP-1 Weight Loss Drug Market Competitive Landscape: Novo Nordisk and Eli Lilly Duopoly, Oral GLP-1 Challengers, and Telehealth Platforms Reshape the Obesity Drug Market Through 2035 The GLP-1 Weight Loss Drug Market competitive landscape is defined by exceptional concentration at the approved drug tier where Novo Nordisk and Eli Lilly collectively control approximately 87% of global prescription obesity drug revenue combined with intense clinical development competition among more than 40 active GLP-1 pipeline programs
Side effects included nausea (44%), vomiting (24%), diarrhea (30%), constipation (24%), abdominal pain (20%), headache (14%), fatigue (11%), dizziness (8%), abdominal distension (7%), and belching (7%)
E., McCammon, J
This approach almost always results in severe nausea, vomiting, and an overall terrible experience that makes the person question whether switching was a good idea at all
Beyond Weight Loss The Growing Impact of GLP-1 Drugs While weight management is the headline most people know, GLP-1 drugs may influence a wide range of health outcomes: Heart Health: Studies suggest reductions in cardiovascular events in people with diabetes and obesity
Amit Doshi Sanjay Shrivastava Jatin Aggarwal Dr
